| 货号 | 18128-1mg |
| 描述 | Elacridar is a dual inhibitor of P-glycoprotein (MRP-1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). It maximally inhibits P-glycoprotein in isolated human peripheral blood leukocytes at 200 nM.1 Elacridar blocks the activity of P-glycoprotein at the blood-brain barrier, altering the pharmacokinetics of certain drugs in the brain.2 This compound is effective against both human BCRP and the mouse homolog, Bcrp1.3,4 |
| 别名 | GF120918;GG918;GW0918; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Witherspoon, S.M.,Emerson, D.L.,Kerr, B.M., et al. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clinical Cancer Research 2, 7-12 (1996). 2.Letrent, S.P.,Pollack, G.M.,Brouwer, K.R., et al. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metabolism and Disposition 27(7), 827-834 (1999). 3.de Bruin, M.,Miyake, K.,Litman, T., et al. Reversal of resistance by GF120918 in cell lines expressing the ABC halftransporter, MXR. Cancer Letters 146(2), 117-126 (1999). 4.Jonker, J.W.,Smit, J.W.,Brinkhuis, R.F., et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. Journal of the National Cancer Institute 92(20), 1651-1656 (2000). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 563.6 |
| 分子式 | C34H33N3O5 |
| CAS号 | 143664-11-3 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |